Kicking off the year with significant momentum, Roche has announced three agreements to expand its oncology portfolio. The company is set to join forces with MediLink Therapeutics in a deal valued at up to US$1 B, aiming to co-develop the antibody-drug conjugate (ADC) candidate, YL211, for solid tumours. Roche has also committed an additional US$30 M to partner with Remix Therapeutics for the development of small molecules that modulate RNA processing and in its third strategic collaboration, the big pharma has collaborated with MOMA Therapeutics, reaching up to US$2 B, to focus on the identification of drug targets associated with the growth of cancer cells.